Literature DB >> 7534464

Assignment of Actinomyces pyogenes-like (CDC coryneform group E) bacteria to the genus Actinomyces as Actinomyces radingae sp. nov. and Actinomyces turicensis sp. nov.

J Wüst1, S Stubbs, N Weiss, G Funke, M D Collins.   

Abstract

In a previous study the authors reported the characterization of some facultatively anaerobic, Gram-positive, non-sporeforming rods which were found in mixed cultures from various infectious processes, including patients with otitis, empyema, perianal abscesses and decubitus ulcers. Phenotypically these organisms closely resembled Actinomyces pyogenes although their precise taxonomic position remained unknown. In the present investigation the authors have determined the 16S rRNA gene sequences of some representative strains of the Actinomyces pyogenes-like bacteria and report the results of a comparative sequence analysis. On the basis of the results of the present and earlier findings two new Actinomyces species, Actinomyces radingae sp. nov. and Actinomyces turicensis sp. nov. are proposed. The type strains are DSM 9169T and DSM 9168T, respectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534464     DOI: 10.1111/j.1472-765x.1995.tb01290.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  18 in total

1.  Development of amplified 16S ribosomal DNA restriction analysis for identification of Actinomyces species and comparison with pyrolysis-mass spectrometry and conventional biochemical tests.

Authors:  V Hall; G L O'Neill; J T Magee; B I Duerden
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Phenotypic identification of Actinomyces and related species isolated from human sources.

Authors:  N Sarkonen; E Könönen; P Summanen; M Könönen; H Jousimies-Somer
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

3.  Identification of clinical isolates of actinomyces species by amplified 16S ribosomal DNA restriction analysis.

Authors:  V Hall; P R Talbot; S L Stubbs; B I Duerden
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Evaluation of four commercial test systems for identification of actinomyces and some closely related species.

Authors:  Anne-Marie Santala; Nanna Sarkonen; Val Hall; Petteri Carlson; Hannele Jousimies-Somer; Eija Könönen
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

5.  Characterization of some actinomyces-like isolates from human clinical sources: description of Varibaculum cambriensis gen nov, sp nov.

Authors:  Val Hall; Matthew D Collins; Paul A Lawson; Roger A Hutson; Enevold Falsen; Elisabeth Inganas; Brian Duerden
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

6.  Seven isolates of Actinomyces turicensis from patients with surgical infections of the anogenital area in a Czech hospital.

Authors:  Eva Chudácková; Lenka Geigerová; Jaroslav Hrabák; Tamara Bergerová; Václav Liska; Josef Scharfen
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

7.  Genome-Based Taxonomic Classification of the Phylum Actinobacteria.

Authors:  Imen Nouioui; Lorena Carro; Marina García-López; Jan P Meier-Kolthoff; Tanja Woyke; Nikos C Kyrpides; Rüdiger Pukall; Hans-Peter Klenk; Michael Goodfellow; Markus Göker
Journal:  Front Microbiol       Date:  2018-08-22       Impact factor: 5.640

Review 8.  Actinomyces and related organisms in human infections.

Authors:  Eija Könönen; William G Wade
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

9.  Subcutaneous fistulae in a patient with femoral hypoplasia due to Actinomyces europaeus and Actinomyces turicensis.

Authors:  A E Zautner; S Schmitz; C Aepinus; A Schmialek; A Podbielski
Journal:  Infection       Date:  2008-10-14       Impact factor: 3.553

10.  Actinomyces cardiffensis sp. nov. from human clinical sources.

Authors:  Val Hall; Mattew D Collins; Roger Hutson; Enevold Falsen; Brian I Duerden
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.